Human trials for a Thai-developed vaccine could begin in November, following successful prior test runs on primates, an official stated.
Due to the promising results of previous tests, 10,000 doses of the prospective covid-19 vaccine are being produced for human trials.
The director of the Bangkok’s Chulalongkorn University vaccine development program, Kiat Ruxrungtham, on the deliberations of the touted vaccine, said:
“At first we were going to send them in June, but it was not easy to plan everything.”
CU-Cov19, the name of the vaccine currently in development by Thai research teams, was hinted by Dr. Ruxrungtham to be available for the public in Thailand next year.
The vaccine development director remarked:
“If everything goes according to plan, the vaccine will be ready for Thailand in the third or fourth quarter next year.”
The Thai-coronavirus vaccine development is a conjoined effort by Chulalongkorn University and the US-based University of Pennsylvania.
CU-Cov19 is among the 19 coronavirus vaccines being developed globally. China is currently at the forefront of the vaccine development, behind Sinovac Biotech Ltd.
Thailand’s vaccine facility is expected to complete its production in October when it will be transferred to a second facility, preparing the vaccine for human trials in November.
Facilities based overseas- Vancouver in Canada and San Diego in the United States – will also produce 10,000 doses for 5,000 people’s trials.
Dr. Ruxrungtham, on the human trials, said:
“[The trials will not accept volunteers] until we receive approval from the Thai Food and Drug Administration and an ethics committee.”
Last May, Thailand initiated the coronavirus vaccine with the tests first conducted on mice and rats, which then eventually scaled onto primate tests later in the month.